View Financial HealthBRAIN Biotech 配当と自社株買い配当金 基準チェック /06BRAIN Biotech配当金を支払った記録がありません。主要情報n/a配当利回り-0.8%バイバック利回り総株主利回り-0.8%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesPrice Target Changed • May 20Price target decreased by 9.1% to €5.50Down from €6.05, the current price target is an average from 3 analysts. New target price is 87% above last closing price of €2.94. Stock is up 32% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.54 last year.Breakeven Date Change • May 20No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.49m in 2028. New consensus forecast suggests the company will make a loss of €5.44m in 2028.お知らせ • May 12BRAIN Biotech AG to Report Fiscal Year 2026 Results on Jan 14, 2027BRAIN Biotech AG announced that they will report fiscal year 2026 results on Jan 14, 2027お知らせ • Feb 02BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026, at 10:00 W. Europe Standard Time.お知らせ • Jan 17BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year.お知らせ • Nov 18+ 1 more updateBRAIN Biotech AG to Report Q3, 2026 Results on Aug 27, 2026BRAIN Biotech AG announced that they will report Q3, 2026 results on Aug 27, 2026お知らせ • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026お知らせ • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.お知らせ • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025Breakeven Date Change • Dec 30Forecast to breakeven in 2027The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.03m in 2027. Average annual earnings growth of 68% is required to achieve expected profit on schedule.Price Target Changed • Nov 14Price target decreased by 26% to €6.30Down from €8.48, the current price target is an average from 4 analysts. New target price is 120% above last closing price of €2.86. Stock is down 27% over the past year. The company is forecast to post a net loss per share of €0.27 next year compared to a net loss per share of €0.38 last year.Breakeven Date Change • Nov 14Forecast breakeven date pushed back to 2027The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule.New Risk • Sep 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (€32.1m market cap, or US$35.9m).Price Target Changed • Aug 31Price target decreased by 20% to €8.38Down from €10.50, the current price target is an average from 4 analysts. New target price is 396% above last closing price of €1.69. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.38 last year.Reported Earnings • Aug 30Third quarter 2024 earnings released: €0.12 loss per share (vs €0.084 loss in 3Q 2023)Third quarter 2024 results: €0.12 loss per share (further deteriorated from €0.084 loss in 3Q 2023). Revenue: €13.6m (flat on 3Q 2023). Net loss: €2.57m (loss widened 39% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025Price Target Changed • Aug 28Price target decreased by 8.9% to €10.00Down from €10.98, the current price target is an average from 4 analysts. New target price is 502% above last closing price of €1.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.32 next year compared to a net loss per share of €0.38 last year.Reported Earnings • May 29Second quarter 2024 earnings released: €0.088 loss per share (vs €0.10 loss in 2Q 2023)Second quarter 2024 results: €0.088 loss per share (improved from €0.10 loss in 2Q 2023). Revenue: €14.8m (up 8.5% from 2Q 2023). Net loss: €1.92m (loss narrowed 15% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025Buy Or Sell Opportunity • Mar 26Now 22% undervaluedOver the last 90 days, the stock has risen 2.0% to €3.54. The fair value is estimated to be €4.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 2.7%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 81% in the next 2 years.お知らせ • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025Breakeven Date Change • Mar 03Forecast breakeven date pushed back to 2026The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 37% per year to 2025. The company is expected to make a profit of €4.27m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule.Reported Earnings • Feb 29First quarter 2024 earnings released: €0.12 loss per share (vs €0.12 loss in 1Q 2023)First quarter 2024 results: €0.12 loss per share (further deteriorated from €0.12 loss in 1Q 2023). Revenue: €13.1m (down 6.3% from 1Q 2023). Net loss: €2.65m (loss widened 4.5% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 17Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: €0.38 loss per share (further deteriorated from €0.30 loss in FY 2022). Revenue: €57.0m (up 13% from FY 2022). Net loss: €8.28m (loss widened 26% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.1%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.New Risk • Sep 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).Price Target Changed • Sep 05Price target decreased by 8.2% to €11.23Down from €12.23, the current price target is an average from 4 analysts. New target price is 148% above last closing price of €4.53. Stock is down 32% over the past year. The company is forecast to post a net loss per share of €0.41 next year compared to a net loss per share of €0.30 last year.お知らせ • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024Reported Earnings • Sep 01Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.8m (up 5.7% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 14Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2024. The company is expected to make a profit of €1.68m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.お知らせ • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024New Risk • Jul 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Share price has been volatile over the past 3 months (6.9% average weekly change).New Risk • Jun 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.9m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Market cap is less than US$100m (€90.9m market cap, or US$99.1m).Reported Earnings • May 30Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022)Second quarter 2023 results: €0.10 loss per share (further deteriorated from €0.073 loss in 2Q 2022). Revenue: €13.8m (up 4.5% from 2Q 2022). Net loss: €2.27m (loss widened 42% from 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024お知らせ • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.Reported Earnings • Mar 03First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022)First quarter 2023 results: €0.12 loss per share (further deteriorated from €0.11 loss in 1Q 2022). Revenue: €14.1m (up 36% from 1Q 2022). Net loss: €2.53m (loss widened 7.3% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 03Forecast breakeven date moved forward to 2024The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €650.0k in 2024. Average annual earnings growth of 104% is required to achieve expected profit on schedule.お知らせ • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023お知らせ • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.Breakeven Date Change • Nov 17Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 71% is required to achieve expected profit on schedule.お知らせ • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.Price Target Changed • Oct 20Price target decreased to €12.91Down from €14.29, the current price target is an average from 4 analysts. New target price is 158% above last closing price of €5.00. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €0.32 next year compared to a net loss per share of €0.25 last year.Price Target Changed • Oct 05Price target increased to €17.50Up from €15.30, the current price target is an average from 3 analysts. New target price is 262% above last closing price of €4.83. Stock is down 52% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €0.25 last year.Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.Reported Earnings • Jun 05Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: €0.073 loss per share (down from €0.10 profit in 2Q 2021). Revenue: €13.2m (up 31% from 2Q 2021). Net loss: €1.60m (down 177% from profit in 2Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 32%. Over the next year, revenue is forecast to grow 20%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Breakeven Date Change • Jun 01No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €83.9k in 2024.Reported Earnings • Feb 27First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: €0.11 loss per share (up from €0.19 loss in 1Q 2021). Revenue: €10.7m (up 29% from 1Q 2021). Net loss: €2.36m (loss narrowed 30% from 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 15%, compared to a 2.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Breakeven Date Change • Feb 04Forecast to breakeven in 2024The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 19% per year to 2023. The company is expected to make a profit of €2.06m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Reported Earnings • Jan 20Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 7.1%, compared to a 5.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 20Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 7.1%, compared to a 5.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Breakeven Date Change • Jan 17No longer forecast to breakevenThe 5 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.43m in 2024. New consensus forecast suggests the company will make a loss of €3.21m in 2024.Reported Earnings • Sep 01Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: €10.1m (up 3.6% from 3Q 2020). Net loss: €2.03m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 18Price target increased to €16.22Up from €14.22, the current price target is an average from 6 analysts. New target price is 53% above last closing price of €10.60. Stock is up 27% over the past year.Breakeven Date Change • Jul 15No longer forecast to breakevenThe 6 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.12m in 2023. New consensus forecast suggests the company will make a loss of €701.5k in 2023.Reported Earnings • May 29Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €11.2m (up 14% from 2Q 2020). Net income: €2.07m (up €4.56m from 2Q 2020). Profit margin: 18% (up from net loss in 2Q 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 28First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €8.41m (down 20% from 1Q 2020). Net loss: €3.36m (loss widened 49% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Feb 16New 90-day high: €9.66The company is up 32% from its price of €7.32 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.Analyst Estimate Surprise Post Earnings • Jan 20Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 37%. Over the next year, revenue is forecast to grow 8.8%, compared to a 4.0% growth forecast for the Chemicals industry in Germany.Analyst Estimate Surprise Post Earnings • Jan 18Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 37%. Over the next year, revenue is forecast to grow 12%, compared to a 4.0% growth forecast for the Chemicals industry in Germany.Reported Earnings • Jan 16Full year 2020 earnings released: €0.52 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €39.1m (down 2.5% from FY 2019). Net loss: €9.68m (loss narrowed 13% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Jan 14New 90-day high: €9.26The company is up 22% from its price of €7.60 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.85 per share.Is New 90 Day High Low • Dec 23New 90-day high: €8.84The company is up 21% from its price of €7.32 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.53 per share.Is New 90 Day High Low • Oct 30New 90-day low: €6.80The company is down 16% from its price of €8.08 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.89 per share.Price Target Changed • Sep 24Price target lowered to €12.77Down from €16.17, the current price target is an average from 5 analysts. The new target price is 74% above the current share price of €7.32. As of last close, the stock is down 36% over the past year.決済の安定と成長配当データの取得安定した配当: BNNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BNNの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場BRAIN Biotech 配当利回り対市場BNN 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BNN)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Chemicals)3.7%アナリスト予想 (BNN) (最長3年)0%注目すべき配当: BNNは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BNNは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BNNの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BNNが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 21:59終値2026/05/21 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BRAIN Biotech AG 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Yi-Dan WangDeutsche BankJan KochDeutsche BankJan KochDeutsche Bank5 その他のアナリストを表示
Price Target Changed • May 20Price target decreased by 9.1% to €5.50Down from €6.05, the current price target is an average from 3 analysts. New target price is 87% above last closing price of €2.94. Stock is up 32% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.54 last year.
Breakeven Date Change • May 20No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.49m in 2028. New consensus forecast suggests the company will make a loss of €5.44m in 2028.
お知らせ • May 12BRAIN Biotech AG to Report Fiscal Year 2026 Results on Jan 14, 2027BRAIN Biotech AG announced that they will report fiscal year 2026 results on Jan 14, 2027
お知らせ • Feb 02BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Jan 17BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year.
お知らせ • Nov 18+ 1 more updateBRAIN Biotech AG to Report Q3, 2026 Results on Aug 27, 2026BRAIN Biotech AG announced that they will report Q3, 2026 results on Aug 27, 2026
お知らせ • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026
お知らせ • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.
お知らせ • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025
Breakeven Date Change • Dec 30Forecast to breakeven in 2027The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.03m in 2027. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
Price Target Changed • Nov 14Price target decreased by 26% to €6.30Down from €8.48, the current price target is an average from 4 analysts. New target price is 120% above last closing price of €2.86. Stock is down 27% over the past year. The company is forecast to post a net loss per share of €0.27 next year compared to a net loss per share of €0.38 last year.
Breakeven Date Change • Nov 14Forecast breakeven date pushed back to 2027The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
New Risk • Sep 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (€32.1m market cap, or US$35.9m).
Price Target Changed • Aug 31Price target decreased by 20% to €8.38Down from €10.50, the current price target is an average from 4 analysts. New target price is 396% above last closing price of €1.69. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.38 last year.
Reported Earnings • Aug 30Third quarter 2024 earnings released: €0.12 loss per share (vs €0.084 loss in 3Q 2023)Third quarter 2024 results: €0.12 loss per share (further deteriorated from €0.084 loss in 3Q 2023). Revenue: €13.6m (flat on 3Q 2023). Net loss: €2.57m (loss widened 39% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025
Price Target Changed • Aug 28Price target decreased by 8.9% to €10.00Down from €10.98, the current price target is an average from 4 analysts. New target price is 502% above last closing price of €1.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.32 next year compared to a net loss per share of €0.38 last year.
Reported Earnings • May 29Second quarter 2024 earnings released: €0.088 loss per share (vs €0.10 loss in 2Q 2023)Second quarter 2024 results: €0.088 loss per share (improved from €0.10 loss in 2Q 2023). Revenue: €14.8m (up 8.5% from 2Q 2023). Net loss: €1.92m (loss narrowed 15% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025
Buy Or Sell Opportunity • Mar 26Now 22% undervaluedOver the last 90 days, the stock has risen 2.0% to €3.54. The fair value is estimated to be €4.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 2.7%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 81% in the next 2 years.
お知らせ • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025
Breakeven Date Change • Mar 03Forecast breakeven date pushed back to 2026The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 37% per year to 2025. The company is expected to make a profit of €4.27m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
Reported Earnings • Feb 29First quarter 2024 earnings released: €0.12 loss per share (vs €0.12 loss in 1Q 2023)First quarter 2024 results: €0.12 loss per share (further deteriorated from €0.12 loss in 1Q 2023). Revenue: €13.1m (down 6.3% from 1Q 2023). Net loss: €2.65m (loss widened 4.5% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 17Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: €0.38 loss per share (further deteriorated from €0.30 loss in FY 2022). Revenue: €57.0m (up 13% from FY 2022). Net loss: €8.28m (loss widened 26% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.1%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
New Risk • Sep 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
Price Target Changed • Sep 05Price target decreased by 8.2% to €11.23Down from €12.23, the current price target is an average from 4 analysts. New target price is 148% above last closing price of €4.53. Stock is down 32% over the past year. The company is forecast to post a net loss per share of €0.41 next year compared to a net loss per share of €0.30 last year.
お知らせ • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024
Reported Earnings • Sep 01Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.8m (up 5.7% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 14Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2024. The company is expected to make a profit of €1.68m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
お知らせ • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024
New Risk • Jul 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Share price has been volatile over the past 3 months (6.9% average weekly change).
New Risk • Jun 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.9m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Market cap is less than US$100m (€90.9m market cap, or US$99.1m).
Reported Earnings • May 30Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022)Second quarter 2023 results: €0.10 loss per share (further deteriorated from €0.073 loss in 2Q 2022). Revenue: €13.8m (up 4.5% from 2Q 2022). Net loss: €2.27m (loss widened 42% from 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024
お知らせ • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.
Reported Earnings • Mar 03First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022)First quarter 2023 results: €0.12 loss per share (further deteriorated from €0.11 loss in 1Q 2022). Revenue: €14.1m (up 36% from 1Q 2022). Net loss: €2.53m (loss widened 7.3% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 03Forecast breakeven date moved forward to 2024The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €650.0k in 2024. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
お知らせ • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023
お知らせ • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.
Breakeven Date Change • Nov 17Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
お知らせ • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.
Price Target Changed • Oct 20Price target decreased to €12.91Down from €14.29, the current price target is an average from 4 analysts. New target price is 158% above last closing price of €5.00. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €0.32 next year compared to a net loss per share of €0.25 last year.
Price Target Changed • Oct 05Price target increased to €17.50Up from €15.30, the current price target is an average from 3 analysts. New target price is 262% above last closing price of €4.83. Stock is down 52% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €0.25 last year.
Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Reported Earnings • Jun 05Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: €0.073 loss per share (down from €0.10 profit in 2Q 2021). Revenue: €13.2m (up 31% from 2Q 2021). Net loss: €1.60m (down 177% from profit in 2Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 32%. Over the next year, revenue is forecast to grow 20%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Jun 01No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €83.9k in 2024.
Reported Earnings • Feb 27First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: €0.11 loss per share (up from €0.19 loss in 1Q 2021). Revenue: €10.7m (up 29% from 1Q 2021). Net loss: €2.36m (loss narrowed 30% from 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 15%, compared to a 2.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Feb 04Forecast to breakeven in 2024The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 19% per year to 2023. The company is expected to make a profit of €2.06m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Reported Earnings • Jan 20Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 7.1%, compared to a 5.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 20Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 7.1%, compared to a 5.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Jan 17No longer forecast to breakevenThe 5 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.43m in 2024. New consensus forecast suggests the company will make a loss of €3.21m in 2024.
Reported Earnings • Sep 01Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: €10.1m (up 3.6% from 3Q 2020). Net loss: €2.03m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 18Price target increased to €16.22Up from €14.22, the current price target is an average from 6 analysts. New target price is 53% above last closing price of €10.60. Stock is up 27% over the past year.
Breakeven Date Change • Jul 15No longer forecast to breakevenThe 6 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.12m in 2023. New consensus forecast suggests the company will make a loss of €701.5k in 2023.
Reported Earnings • May 29Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €11.2m (up 14% from 2Q 2020). Net income: €2.07m (up €4.56m from 2Q 2020). Profit margin: 18% (up from net loss in 2Q 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 28First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €8.41m (down 20% from 1Q 2020). Net loss: €3.36m (loss widened 49% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Feb 16New 90-day high: €9.66The company is up 32% from its price of €7.32 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.
Analyst Estimate Surprise Post Earnings • Jan 20Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 37%. Over the next year, revenue is forecast to grow 8.8%, compared to a 4.0% growth forecast for the Chemicals industry in Germany.
Analyst Estimate Surprise Post Earnings • Jan 18Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 37%. Over the next year, revenue is forecast to grow 12%, compared to a 4.0% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Jan 16Full year 2020 earnings released: €0.52 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €39.1m (down 2.5% from FY 2019). Net loss: €9.68m (loss narrowed 13% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Jan 14New 90-day high: €9.26The company is up 22% from its price of €7.60 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.85 per share.
Is New 90 Day High Low • Dec 23New 90-day high: €8.84The company is up 21% from its price of €7.32 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.53 per share.
Is New 90 Day High Low • Oct 30New 90-day low: €6.80The company is down 16% from its price of €8.08 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.89 per share.
Price Target Changed • Sep 24Price target lowered to €12.77Down from €16.17, the current price target is an average from 5 analysts. The new target price is 74% above the current share price of €7.32. As of last close, the stock is down 36% over the past year.